Dataset Information

Understanding the role of antibiotic-associated adverse events in influencing antibiotic decision-making.

ABSTRACT:

Objective

To (1) understand the role of antibiotic-associated adverse events (ABX-AEs) on antibiotic decision-making, (2) understand clinician preferences for ABX-AE feedback, and (3) identify ABX-AEs of greatest clinical concern.

Design

Focus groups.

Setting

Academic medical center.

Participants

Medical and surgical house staff, attending physicians, and advanced practice practitioners.

Methods

Focus groups were conducted from May 2022 to December 2022. Participants discussed the role of ABX-AEs in antibiotic decision-making and feedback preferences and evaluated the prespecified categorization of ABX-AEs based on degree of clinical concern. Thematic analysis was conducted using inductive coding.

Results

Four focus groups were conducted (n = 15). Six themes were identified. (1) ABX-AE risks during initial prescribing influence the antibiotic prescribed rather than the decision of whether to prescribe. (2) The occurrence of an ABX-AE leads to reassessment of the clinical indication for antibiotic therapy. (3) The impact of an ABX-AE on other management decisions is as important as the direct harm of the ABX-AE. (4) ABX-AEs may be overlooked because of limited feedback regarding the occurrence of ABX-AEs. (5) Clinicians are receptive to feedback regarding ABX-AEs but are concerned about it being punitive. (6) Feedback must be curated to prevent clinicians from being overwhelmed with data. Clinicians generally agreed with the prespecified categorizations of ABX-AEs by degree of clinical concern.

Conclusions

The themes identified and assessment of ABX-AEs of greatest clinical concern may inform antibiotic stewardship initiatives that incorporate reporting of ABX-AEs as a strategy to reduce unnecessary antibiotic use.

SUBMITTER: Cherian JP

PROVIDER: S-EPMC10897715 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Understanding the role of antibiotic-associated adverse events in influencing antibiotic decision-making.

Cherian Jerald P JP Helsel Taylor N TN Jones George F GF Virk Zunaira Z Salinas Alejandra A Grieb Suzanne M SM Klein Eili Y EY Tamma Pranita D PD Cosgrove Sara E SE

Antimicrobial stewardship & healthcare epidemiology : ASHE 20240130 1

<h4>Objective</h4>To (1) understand the role of antibiotic-associated adverse events (ABX-AEs) on antibiotic decision-making, (2) understand clinician preferences for ABX-AE feedback, and (3) identify ABX-AEs of greatest clinical concern.<h4>Design</h4>Focus groups.<h4>Setting</h4>Academic medical center.<h4>Participants</h4>Medical and surgical house staff, attending physicians, and advanced practice practitioners.<h4>Methods</h4>Focus groups were conducted from May 2022 to December 2022. Parti ...[more]

PMID: 38415083

Similar Datasets

Project description:BackgroundThere is sparse high-level evidence to guide treatment decisions for severe, acute cholecystitis (inflammation of the gallbladder). Therefore, treatment decisions depend heavily on individual surgeon judgment, which is highly variable and potentially amenable to personalized, data-driven decision support. We test the hypothesis that surgeons' treatment recommendations misalign with perceived risks and benefits for laparoscopic cholecystectomy (surgical removal) vs. percutaneous cholecystostomy (image-guided drainage).MethodsSurgery attendings, fellows, and residents applied individual judgement to standardized case scenarios in a live, web-based survey in estimating the quantitative risks and benefits of laparoscopic cholecystectomy vs. percutaneous cholecystostomy for both moderate and severe acute cholecystitis, as well as the likelihood that they would recommend cholecystectomy.ResultsSurgeons predicted similar 30-day morbidity rates for laparoscopic cholecystectomy and percutaneous cholecystostomy. However, a greater proportion of surgeons predicted low (<50%) likelihood of full recovery following percutaneous cholecystostomy compared with cholecystectomy for both moderate (30% vs. 2%, p < 0.001) and severe (62% vs. 38%, p < 0.001) cholecystitis. Ninety-eight percent of all surgeons were likely or very likely to recommend cholecystectomy for moderate cholecystitis; only 32% recommended cholecystectomy for severe cholecystitis (p < 0.001). There were no significant differences in predicted postoperative morbidity when respondents were stratified by academic rank or self-reported ability to predict complications or make treatment recommendations.ConclusionsSurgeon recommendations for severe cholecystitis were discordant with perceived risks and benefits of treatment options. Surgeons predicted greater functional recovery after cholecystectomy but less than one-third recommended cholecystectomy. These findings suggest opportunities to augment surgical decision-making with personalized, data-driven decision support.

Dataset Information

Understanding the role of antibiotic-associated adverse events in influencing antibiotic decision-making.

Objective

Design

Setting

Participants

Methods

Results

Conclusions

Publications

Understanding the role of antibiotic-associated adverse events in influencing antibiotic decision-making.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets